Tag: Weight Loss
ACS: 2020 to 2024 Saw Jump in Use of GLP-1 Receptor Agonists Before Metabolic,...
Even higher use seen in patients without type 2 diabetes
Weight-Loss Treatment Tied to Lower Risk for Obesity-Related Cancers
Findings seen for both medication and surgical procedures in people with obesity and type 2 diabetes
Costco to Sell Ozempic and Wegovy for $499 a Month
The same price is already available on Novo Nordisk’s direct-to-consumer website, as well as at Walmart and CVS
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
Risk reductions stronger in those with psoriasis versus those with obesity or type 2 diabetes without psoriasis
Oral Semaglutide Effective for Weight Loss in Overweight or Obesity
Estimated mean change in body weight from baseline to week 64 was −13.6 and −2.2 percent with oral semaglutide and placebo, respectively
Oral Orforglipron Yields Greater Weight Reductions Than Placebo
Significant mean change in body weight from baseline to week 72 seen with various dosages of orforglipron compared with placebo among adults with obesity
Once-Weekly Semaglutide 7.2 mg Beats Placebo for Obesity
Second study shows 7.2 mg semaglutide leads to greater reductions in mean body weight for those with obesity, T2D
Weight-Loss Surgery Bests Medical Weight Management for Obesity-Related Risk Mitigation
Significantly lower risk seen for developing major metabolic comorbidities
Half Discontinue Semaglutide for Weight Loss Within One Year
Factors tied to discontinuation included younger age, male sex, socioeconomic deprivation, higher comorbidity level
FDA Creates ‘Green List’ of GLP-1 Drug Ingredients Approved for Entry in the U.S.
The purpose of the list is to keep unverified and unapproved GLP-1 drug ingredients from entering the country
